RevMedica becomes the only Endo Stapling
Platform accepted into FDA's STeP. The Company also expands its
intellectual property protection with 5 new patents.
MIDDLETOWN, Conn., Jan. 22,
2025 /PRNewswire/ -- RevMedica™, Inc. is pleased to
announce its' Endo Stapling Platform has been accepted into the
U.S. Food and Drug Administration's (FDA's) Safer Technologies
Program (STeP).
Acceptance into the FDA's Safer Technologies Program is reserved
for "medical devices that are reasonably expected to significantly
improve the safety of currently available treatments." The program
is intended to expedite development, assessment, and regulatory
review by means of interactive communication with the FDA as the
program progresses.
"The STeP designation offers additional validation of the unique
advantages of our stapling platform," states Tom Wenchell, Chief Executive Officer,
RevMedica. "This is the product of many years spent listening to
surgeons describe their need for objective, real-time data
currently lacking in today's stapling devices. We are fortunate to
have such an experienced team of surgical stapling experts on staff
to make this product a reality." Tom will be participating in a
panel discussion at the SAGES[1] NBT Innovation Weekend
on "My Favorite Unmet Surgical Need," Saturday, January 25th, to highlight
these advancements.
Also, RevMedica announced the expansion of its intellectual
property portfolio through the issuance of 5 new U.S. Patents,
bringing the total to 20 US and 5 foreign issued patents. "We
continue to build a strong foundation to bolster our unique
offering and will continue to protect these advancements in the
U.S. and abroad," concluded Tom.
About RevMedica
RevMedica, backed by Telegraph Hill Partners, is a pioneering
medical technology company set to revolutionize the way surgeons
approach soft tissue management. With a mission focused on
optimizing clinical decision-making and elevating patient safety,
RevMedica aims to achieve these objectives through the development
of cost-effective, environmentally-friendly, surgical systems.
RevMedica is passionate about delivering enabling technology,
better clinical results and a more sustainable healthcare
ecosystem. Learn more at revmedica.com
For further information, please contact:
Thomas Wenchell, Chief Executive Officer
RevMedica, Inc.
Email: Tom@RevMedica.com
revmedica.com
[1] SAGES is the Society Of American Gastrointestinal and
Endoscopic Surgeons and more information about the NBT Innovation
weekend can be found at
https://www.sages.org/sages-nbt-innovation-weekend/.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/revmedica-gains-fda-safer-technologies-program-step-acceptance-and-expands-ip-portfolio-302357792.html
SOURCE RevMedica, Inc.
